EUVIMEDEUVIMED entdecken
Crossref

Enhanced prognostic evaluation of diffuse large B‐cell lymphoma: A comprehensive surveillance study incorporating Epstein–Barr virus infection status and immunohistochemical markers

Meichun Zeng iD, Qingjun Jia, Jingjing Chen

Journal of Medical Virology · 2024-08 · 96 (8)

DOI: 10.1002/jmv.29834 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, online erschienen am 02.08.2024. Verfasst von Meichun Zeng und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Epstein-Barr Virus Infections, Herpesvirus 4, Human. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Emerging biologic subsets and new prognostic markers are significantly important for aggressive diffuse large B‐cell lymphoma (DLBCL). Nevertheless, the high cost of testing limits the availability of these tests in most hospitals, thus making prognostic judgment based on basic immunohistochemical testing, whole blood Epstein–Barr virus DNA (WBEBV) surveillance and clinical features advantageous for hospitals and patients with poor medical conditions. We included 647 DLBCL patients treated in our hospital from January 2009 to March 2023. Non‐germinal center B‐cell like, Ki‐67, and International Prognostic Index (IPI) scores were related to cMYC/B‐cell lymphoma 2 (Bcl‐2)‐double expression. Age, Epstein–Barr virus‐encoded small RNA (EBER) positivity, and IPI scores were associated with mortality. The cutoffs for differential overall survival (OS) of age, WBEBV, Bcl‐2, and cMYC were 57 years, 1514 copies/mL (baseline), 5.89 × 10 4 copies/mL (treatment), 40%, and 55%, respectively. EBER positivity was significantly associated with a worse OS. Patients with newly defined DE (Bcl‐2 ≥ 40 and cMYC > 55) had a worse prognosis than controls ( p = 0.04). We found that cMYC with an optimal cutoff of 47.5 could effectively predict high‐grade DLBCL with an area under the curve of 0.912, and the specificity and sensitivity were 70.7% and 100%, respectively. Our study provides valuable insights into the prognostic factors and biomarker cutoffs that influence OS in DLBCL patients, which may guide clinicians in tailoring treatment strategies and improving patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseEpstein-Barr Virus InfectionsHerpesvirus 4, HumanHumansMaleFemaleMiddle AgedPrognosisAgedAdultAged, 80 and overImmunohistochemistryYoung AdultDNA, ViralBiomarkers, TumorAdolescentProto-Oncogene Proteins c-bcl-2Retrospective Studies

Stichwörter der Autor:innen

Epstein–Barr virusEpstein–Barr virus‐encoded small RNAdiffuse large B‐cell lymphomadouble expressionimmunohistochemistry

Substanzen

DNA, ViralBiomarkers, TumorProto-Oncogene Proteins c-bcl-2

Autor:innen und Institutionen

  • Department of Pathology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
  • Hangzhou Center for Disease Control and Prevention (Hangzhou Health Supervision Institution), Hangzhou, China.

ORCID-Profile: Meichun Zeng

Zitieren

APA

Zeng, M., Jia, Q., & Chen, J. (2024). Enhanced prognostic evaluation of diffuse large B‐cell lymphoma: A comprehensive surveillance study incorporating Epstein–Barr virus infection status and immunohistochemical markers. Journal of Medical Virology, 96(8). https://doi.org/10.1002/jmv.29834

Vancouver

Zeng M, Jia Q, Chen J. Enhanced prognostic evaluation of diffuse large B‐cell lymphoma: A comprehensive surveillance study incorporating Epstein–Barr virus infection status and immunohistochemical markers. Journal of Medical Virology. 2024;96(8). doi:10.1002/jmv.29834

BibTeX
@article{Zeng2024,
  author = {Zeng, Meichun and Jia, Qingjun and Chen, Jingjing},
  title = {Enhanced prognostic evaluation of diffuse large B‐cell lymphoma: A comprehensive surveillance study incorporating Epstein–Barr virus infection status and immunohistochemical markers},
  journal = {Journal of Medical Virology},
  year = {2024},
  volume = {96},
  number = {8},
  doi = {10.1002/jmv.29834}
}
Kostenlos starten →